It has been demonstrated that more than 50% of t(8;21) AML patients present with aberrant CD19 expression on leukemic blasts (13), which indicates that CD19 is a promising target for CAR-T cell therapy in CD19-positive t(8;21) AML patients. Here, CD19 is linked to acute myeloid leukemia.